BR112022019571A2 - Método para editar um ácido ribonucleico alvo, domínio dyw, proteína dyw, composição para editar ácido ribonucleico em uma célula eucariótica, ácido nucleico, vetor, e, célula - Google Patents

Método para editar um ácido ribonucleico alvo, domínio dyw, proteína dyw, composição para editar ácido ribonucleico em uma célula eucariótica, ácido nucleico, vetor, e, célula

Info

Publication number
BR112022019571A2
BR112022019571A2 BR112022019571A BR112022019571A BR112022019571A2 BR 112022019571 A2 BR112022019571 A2 BR 112022019571A2 BR 112022019571 A BR112022019571 A BR 112022019571A BR 112022019571 A BR112022019571 A BR 112022019571A BR 112022019571 A2 BR112022019571 A2 BR 112022019571A2
Authority
BR
Brazil
Prior art keywords
dyw
editing
target
ribonucleic acid
cell
Prior art date
Application number
BR112022019571A
Other languages
English (en)
Portuguese (pt)
Inventor
Ichinose Mizuho
gutmann Bernard
Yagi Yusuke
Akaiwa Yumi
Shimajiri Yasuka
Nakamura Takahiro
Original Assignee
Editforce Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Editforce Inc filed Critical Editforce Inc
Publication of BR112022019571A2 publication Critical patent/BR112022019571A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/415—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102—Mutagenizing nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Botany (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Mycology (AREA)
  • Cell Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
BR112022019571A 2020-03-31 2021-03-31 Método para editar um ácido ribonucleico alvo, domínio dyw, proteína dyw, composição para editar ácido ribonucleico em uma célula eucariótica, ácido nucleico, vetor, e, célula BR112022019571A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2020065065 2020-03-31
PCT/JP2021/014096 WO2021201198A1 (ja) 2020-03-31 2021-03-31 標的ｒｎａを編集する方法

Publications (1)

Publication Number Publication Date
BR112022019571A2 true BR112022019571A2 (pt) 2022-12-06

Family

ID=77930108

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022019571A BR112022019571A2 (pt) 2020-03-31 2021-03-31 Método para editar um ácido ribonucleico alvo, domínio dyw, proteína dyw, composição para editar ácido ribonucleico em uma célula eucariótica, ácido nucleico, vetor, e, célula

Country Status (11)

Country Link
US (1) US20230125942A1 (enExample)
EP (1) EP4130274A4 (enExample)
JP (4) JP7668547B2 (enExample)
KR (1) KR20220165747A (enExample)
CN (1) CN115698296A (enExample)
AU (1) AU2021248204A1 (enExample)
BR (1) BR112022019571A2 (enExample)
CA (1) CA3179365A1 (enExample)
IL (1) IL296955A (enExample)
TW (1) TWI899197B (enExample)
WO (1) WO2021201198A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3216313A1 (en) * 2021-04-30 2022-11-03 Masayuki NAKAMORI Myotonic dystrophy type 1 therapeutic drug
JPWO2023120658A1 (enExample) * 2021-12-24 2023-06-29
WO2024249445A2 (en) * 2023-05-26 2024-12-05 The Trustees Of Columbia University In The City Of New York An rna recognition and editing code of pentatricopeptide repeat proteins
CN117384884B (zh) * 2023-11-30 2024-03-08 辉大(上海)生物科技有限公司 IscB多肽及其用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009134339A2 (en) * 2008-04-29 2009-11-05 Monsanto Technology, Llc Genes and uses for plant enhancement
DK2784157T3 (da) * 2011-10-21 2019-10-21 Univ Kyushu Nat Univ Corp Designfremgangsmåde til et rna-bindende protein under anvendelse af ppr-motiv og anvendelse deraf
AU2014258386B2 (en) 2013-04-22 2018-10-25 Hiroshima University DNA binding protein using PPR motif, and use thereof

Also Published As

Publication number Publication date
JP7668547B2 (ja) 2025-04-25
JP7698371B1 (ja) 2025-06-25
JP2025120313A (ja) 2025-08-15
IL296955A (en) 2022-12-01
EP4130274A1 (en) 2023-02-08
CA3179365A1 (en) 2021-10-07
TW202204382A (zh) 2022-02-01
JP2024096897A (ja) 2024-07-17
WO2021201198A1 (ja) 2021-10-07
EP4130274A4 (en) 2024-05-22
JP2025107239A (ja) 2025-07-17
AU2021248204A1 (en) 2022-11-10
US20230125942A1 (en) 2023-04-27
JPWO2021201198A1 (enExample) 2021-10-07
TWI899197B (zh) 2025-10-01
JP7698351B2 (ja) 2025-06-25
CN115698296A (zh) 2023-02-03
KR20220165747A (ko) 2022-12-15

Similar Documents

Publication Publication Date Title
BR112022019571A2 (pt) Método para editar um ácido ribonucleico alvo, domínio dyw, proteína dyw, composição para editar ácido ribonucleico em uma célula eucariótica, ácido nucleico, vetor, e, célula
BR112022008415A2 (pt) Composições e métodos para substituição do dna codificado pelo rna dos alelos
Martin-Pérez et al. Ordered phosphorylation of 40S ribosomal protein S6 after serum stimulation of quiescent 3T3 cells.
BR112019011277A2 (pt) polinucleotídeo, sistema de expressão recombinante, vetor, polipeptídeo, célula recombinante, polipeptídeo de receptor imune sintético isolado ou heterodímero de polipeptídeo, célula efetora imune ou célula-tronco, população de células imunes ou efetoras, métodos de fabricação de uma célula efetora imune que expressa sir, de geração de uma população de células modificadas por rna, de fornecimento de imunidade antidoença e de tratamento ou prevenção de uma doença, composição, uso ou método, kit, e, sequência de aminoácidos.
BR112022021789A2 (pt) Bibliotecas de ácido nucléico variantes para coronavírus
BR112022011235A2 (pt) Bibliotecas de variantes de ácido nucleico para receptores de adenosina
BR112020024863A2 (pt) Nucleases guiadas por rna, fragmentos ativos e variantes das mesmas e métodos de uso
BR112022002695A2 (pt) Nucleases guiadas por rna, fragmentos ativos e variantes das mesmas e métodos de uso
BR112022021459A2 (pt) Nucleases guiadas por rna, fragmentos ativos e variantes das mesmas e métodos de uso
BR9708209A (pt) Polipeptídeo isolado tendo atividade fitase sequência de ácido nucleico isolada construção de ácido nucleico vetor de expressão recombinante célula hospedeira recombinante processo para produzir o polipeptídeo composição de alimento ou ração processo para reduzir os níveis de fitato em estrume de animais processo para liquefazer um amido e uso de um polipeptídeo
SG141233A1 (en) Control of gene expression
PE20110310A1 (es) Axmi-115, axmi-113, axmi-005, axmi-163 y axmi-184: proteinas insecticidas
BR112022014272A2 (pt) Fator de crescimento derivado de mieloide para uso no tratamento ou prevenção de fibrose, hipertrofia ou insuficiência cardíaca
BR0107703A (pt) Flavivìrus recombinantes e processos para uso dos mesmos
Yuen et al. Nonmuscle myosin is regulated during smooth muscle contraction
BR112023025730A2 (pt) Sistemas de transpóson-crispr para modificação de dna, sistema ou kit, composição, célula, método para integração de dna e uso do dito sistema
Schneider et al. Posttranslational modifications of trichomonad tubulins; identification of multiple glutamylation sites
Zhang et al. Identification of novel alternative splicing transcript and expression analysis of bovine TMEM95 gene
Mazina et al. Nuclear receptors EcR, Usp, E75, DHR3, and ERR regulate transcription of ecdysone cascade genes
JP2024096897A5 (enExample)
BR112021017491A2 (pt) Receptores de células t e métodos de uso dos mesmos
CL2025002637A1 (es) Proteínas de ingeniería y métodos de uso.
BR112023015160A2 (pt) Compostos e métodos para reduzir a expressão de pln
BR9712587A (pt) ‡cido nucléico, molécula de ácido nucléico, sonda, vetor de expressão recombinante, célula, processos para produzir um polipeptìdeo de h. pylori e para detectar a presença de um ácido nucléico de helicobacter pylori em uma amostra, polipeptìdeo de h. pylori isolado, polipeptìdeos de envelope de célula, celular e secretado de h. pylori ou seus fragmentos, proteìna de fusão, formulação de vacina para a profilaxia ou tratamento de uma infecção por h. pylori, e, processos para tratar ou reduzir um risco de infecção por h. pylori em um sujeito e para produzir uma formulação de vacina.
TR200000288T2 (tr) İnsülin C-peptidin rekombinan ekspresyonu.

Legal Events

Date Code Title Description
B25G Requested change of headquarter approved

Owner name: EDITFORCE, INC. (JP)